Press Releases

Exercise of Tranche 2 Warrants by Crystal Amber and Appendix 3B

BOSTON and SYDNEY — 4 October 2019 — GI Dynamics® Inc. (ASX:GID) (Company or GI Dynamics), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that further to the announcements made by the Company on 22 August 2019 and 29...

read more

GI Dynamics Announces up to ~US$10 Million Financing with Crystal Amber – Defers Potential ASX Delisting – Extends Maturity Date of 2017 Convertible Note – General Corporate Update

BOSTON and SYDNEY — 22 August 2019 — GI Dynamics® Inc. (ASX:GID) (Company or GI Dynamics), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce that it has agreed to the terms of a financing (Financing) with Crystal Amber...

read more

Confirmation of Conversion of 3 of 4 Convertible Notes by Crystal Amber

BOSTON and SYDNEY – 2 July 2019 – GI Dynamics® Inc. (ASX: GID) (the Company), a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity confirms that, following the Company’s announcement on 1 July 2019, it has today issued a total of 453,609,963 CHESS...

read more

Issue of Warrants and Notice of Conversion of Convertible Notes

BOSTON and SYDNEY – 1 July 2019 – GI Dynamics® Inc. (ASX: GID) (the Company) medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity confirms that, following the holding of its 2019 Annual Meeting of Stockholders, it has issued certain warrants...

read more

Results of 2019 Annual Meeting of Stockholders

BOSTON and SYDNEY – 1 July 2019 – GI Dynamics® Inc. (ASX: GID) (the Company) held its Annual Meeting of Stockholders on 30 June 2019 and in accordance with ASX Listing Rule 3.13.2, is pleased to announce that each of the resolutions put to stockholders as set forth in the Proxy Statement dated 20...

read more

Videos